Given the prognostic and treatment implications, testing for FLT3-ITD in patients with newly diagnosed AML is recommended by both ELN and National Comprehensive Cancer Network (NCCN) guidelines (8, 11). Here, FLT3 is linked to acute myeloid leukemia.